Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech Alnylam Pharmaceuticals
So what: As with most biotech companies, today's story has very little to do with the fact that Alnylam met Wall Street's estimates with a loss of $0.33 -- but has everything to do with its cash burn rate. In fiscal 2011, Alnylam burned through $89 million in cash. Its fiscal 2012 forecast anticipates that the company will end the year with "greater than $180 million at December 31, 2012." This implies a cash burn rate of up to $80 million more.
Now what: Alnylam has already had a huge run, doubling in price since late November. The RNAi therapeutics company currently has three experimental therapies in phase 1 clinical trials and one in phase 2 trials. Partnered with Cubist Pharmaceuticals
Craving more input? Start by adding Alnylam Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.